A detailed history of Elequin Capital LP transactions in Repligen Corp stock. As of the latest transaction made, Elequin Capital LP holds 35 shares of RGEN stock, worth $4,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35
Holding current value
$4,990
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$119.79 - $167.35 $4,192 - $5,857
35 New
35 $5,000
Q3 2023

Nov 14, 2023

SELL
$138.78 - $176.51 $20,123 - $25,593
-145 Reduced 94.77%
8 $1,000
Q2 2023

Aug 14, 2023

BUY
$138.42 - $180.31 $21,178 - $27,587
153 New
153 $21,000
Q4 2022

Feb 09, 2023

BUY
$162.42 - $220.56 $1,136 - $1,543
7 New
7 $1,000
Q2 2022

Aug 11, 2022

SELL
$140.68 - $188.02 $844 - $1,128
-6 Reduced 25.0%
18 $3,000
Q1 2022

May 16, 2022

BUY
$161.19 - $257.96 $3,062 - $4,901
19 Added 380.0%
24 $5,000
Q4 2021

Feb 15, 2022

BUY
$247.59 - $304.47 $1,237 - $1,522
5 New
5 $1,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $7.91B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Elequin Capital LP Portfolio

Follow Elequin Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Elequin Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Elequin Capital LP with notifications on news.